Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07859202
PHASE3
The Purpose of This Study is to Evaluate the Efficacy and Safety of W2505.
Sponsor: GL Pharm Tech Corporation
View on ClinicalTrials.gov
Summary
The purpose of this study is to evaluate the efficacy and safety of W2505.
Official title: A Prospective, Multi-center, Randomized, Double-blinded, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of W2505
Key Details
Gender
MALE
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
228
Start Date
2026-09
Completion Date
2027-07
Last Updated
2026-10-05
Healthy Volunteers
No
Conditions
Interventions
DRUG
W2505
PO, Once daily(QD), 12 weeks
DRUG
W2505-P1
PO, Once daily(QD), 12 weeks
DRUG
W2505-R
PO, Once daily(QD), 12 weeks
DRUG
W2505-P2
PO, Once daily(QD), 12 weeks
Locations (1)
Inha University Hospital
Incheon, South Korea